Scotiabank Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $44.00

Keros Therapeutics (NASDAQ:KROS) had its price target lowered by Scotiabank from $77.00 to $44.00 in a report released on Friday morning,Benzinga reports. The firm currently has a sector outperform rating on the stock.

Several other research firms have also weighed in on KROS. Bank of America lowered their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. HC Wainwright lowered their price target on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday. Jefferies Financial Group began coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating for the company. Wedbush reissued an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $85.67.

Keros Therapeutics Stock Performance

KROS opened at $18.83 on Friday. The business’s 50-day simple moving average is $59.11 and its 200 day simple moving average is $52.69. Keros Therapeutics has a 52-week low of $15.67 and a 52-week high of $73.00. The firm has a market capitalization of $762.75 million, a PE ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.33) EPS. On average, research analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares in the last quarter. KBC Group NV raised its position in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after purchasing an additional 1,033 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Algert Global LLC increased its stake in shares of Keros Therapeutics by 10.6% in the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock valued at $717,000 after buying an additional 1,505 shares during the period. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.